Prevention of Recurrent Aphthous Stomatitis Using Vitamins
Prevention of Recurrent Aphthous Stomatitis Using Vitamins
The purpose of this research study is to find out if taking a multivitamin daily can affect
 the number of canker sores that people get and how long they last. Previous studies have
 shown that people who get canker sores are more likely to be deficient in one or more
 vitamins. It has also been found that correction of such vitamin deficiencies reduces the
 number and duration of canker sores. However, it is not known if taking a multivitamin daily
 will reduce the number and duration of canker sores.
Inclusion Criteria:

 -  Patients willing and able to provide written informed consent for the study

 -  Patients with a history of at least three episodes of minor recurrent aphthous
 stomatitis (RAS) within the past one year

 Exclusion Criteria:

 -  Patients with a history of other forms of RAS (major, herpetiform)

 -  Patients who will be using any other vitamins/supplements during the study or those
 who have used any vitamins/supplements on a regular basis during the 90 days
 immediately preceding enrollment onto the study (regular use is defined as continuous
 daily use for at least a two week period)

 -  Patients who are under the age of 18

 -  Women who are pregnant or nursing or those who plan to become pregnant

 -  Patients with a history of gout, kidney stones or iron overload disease

 -  Patients who currently smoke tobacco products

 -  Patients who are former smokers who have quit smoking within the past 30 days

 -  Patients with sulfite allergy

 -  Patients with a history of any systemic condition associated with oral ulceration.
 These include: Behcet's syndrome, Sweet's syndrome, Celiac disease, Crohn's disease,
 ulcerative colitis, HIV infection/AIDS, cyclic neutropenia and PFAPA syndrome
 (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis)

 -  Patients on medications commonly associated with causing oral ulceration. These
 include nicorandil, methotrexate and chemotherapeutic agents used for cancer.

 -  Patients using oral topical anti-inflammatory agents during the course of the study

 -  Patients who plan to use any products specifically for management of RAS lesions

 -  Patients who are routinely using agents that could have an impact on duration of RAS
 lesions (e.g., antibacterial mouthrinses)

 -  Patients receiving any other investigational agent during the course of ths study

 -  Patients with any other condition that might preclude participation in the study in
 the opinion of the study investigators